Mortality in systemic sclerosis-a single centre study from the UK

Gemma Strickland1, John Pauling, Charlotte Cavill

  • 1Royal National Hospital for Rheumatic Diseases, Bath, UK, GemmaStrickland@hotmail.com.

Insights

Systemic sclerosis (SSc) patients face increased mortality compared to the general population, with infection, respiratory disease, and malignancy being leading causes. Older age at diagnosis, male gender, interstitial lung disease, and anti-RNA polymerase III antibodies predict poorer survival.

Area of Science:

  • Rheumatology
  • Clinical Epidemiology
  • Immunology

Background:

  • Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis and vascular abnormalities.
  • Understanding mortality patterns and predictors in SSc is crucial for improving patient outcomes.
  • Previous studies have reported varying mortality rates in SSc cohorts.

Purpose of the Study:

  • To determine the causes and predictors of mortality in a cohort of patients with systemic sclerosis (SSc).
  • To compare the mortality rate of SSc patients with the general population.
  • To identify factors influencing survival in SSc.

Main Methods:

  • Retrospective analysis of 204 SSc patients from the Royal National Hospital for Rheumatic Diseases database (1999-2010).
  • Mortality data obtained from the NHS Strategic Tracing Service and UK Registry of Births, Marriages and Deaths.
  • Standardized mortality ratio (SMR) calculation, Kaplan-Meier survival estimates, and proportional hazards regression for predictor analysis.

Main Results:

  • The overall SMR was 1.34, indicating a higher mortality rate than the general population.
  • Leading causes of death included infection, respiratory disease, and malignancy, with pulmonary complications being the most common SSc-related cause.
  • Predictors of adverse survival were older age at diagnosis, male gender, interstitial lung disease (ILD), and anti-RNA polymerase III antibody positivity.

Conclusions:

  • The SSc cohort exhibited increased mortality compared to the general population, particularly in males.
  • Pulmonary complications remain a significant cause of SSc-related mortality.
  • Identifying specific clinical and serological factors aids in predicting survival and guiding management strategies for SSc patients.